2,5-Cyclohexadiene-1,4-dione, 2-(2,5-dichlorophenyl)-, 98%, 100mg

DBD-NCS [=4-(N,N-Dimethylaminosulfonyl)-7-isothiocyanato-2,1,3-benzoxadiazole] [for HPLC Labeling and Edman Degradation]100mg

2-(2-Bromoethyl)-1,3-difluorobenzene, 95%, 5g

1-(2-Ethylpiperidin-1-yl)nonan-1-one, 90.0%, 100mg

Methyl (r)-3-amino-3-(3-fluorophenyl)propanoate, 98%, 250mg

Syrosingopine, 99.23%, 250mg

7-Methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one, 95.0%, 1g

4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid, 97.0%, 10g

2-[3-(2-Dimethylamino-5-trifluoromethyl-pyridin-3-yl)-phenoxy]-propionic acid ethyl ester, 95.0%, 1g

2,6-Difluoropyridine-3-boronic acid, 97.0%, 1g

3-Azabicyclo[4.1.0]heptane-3-carboxylic acid, 5-hydroxy-, 1,1-dimethylethyl ester, 98%, 1g

4,7-Di(2-thienyl)-2,1,3-benzothiadiazole>98.0%(HPLC)(N)200mg

4,4,5,5-Tetramethyl-2-(2,2,6,6-tetramethyl-3,6-dihydro-2H-pyran-4-yl)-1,3,2-dioxaborolane, 95.0%, 250mg